REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 15, 2015--
Heron Therapeutics, Inc. (NASDAQ: HRTX), today announced closing of its
underwritten public offering of 5,520,000 shares of common stock,
including 720,000 shares sold pursuant to the full exercise of an option
to purchase additional shares previously granted to the underwriters, at
a public offering price of $24.75 per share. The gross offering size was
approximately $136.6 million before deducting customary underwriting
discounts and commissions and offering expenses.
Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC acted as
joint book-running managers for the offering. JMP Securities LLC, Brean
Capital, LLC and Noble Life Science Partners acted as co-managers for
The securities described above were offered pursuant to shelf
registration statements (File Nos. 333-195928 and 333-198862), which
were declared effective by the United States Securities and Exchange
Commission (“SEC”) on May 23, 2014 and October 6, 2014, respectively.
The securities described above have not been qualified under any state
blue sky laws. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction. The offering can be made only by means of a
prospectus, copies of which may be obtained at the SEC’s website at www.sec.gov,
or by request at Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022,
telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com.
This press release includes forward-looking statements, including
statements relating to the proceeds of the offering and closing of the
offering. For these statements, Heron Therapeutics, Inc. claims the
protection of the safe harbor for forward-looking statements provided by
the Private Securities Litigation Reform Act of 1995. It should be noted
that there are risks and uncertainties related to the public offering. A
review of these risks can be found in Heron Therapeutics, Inc.’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2014, the
prospectus filed with the SEC in connection with the offering and other
reports and documents filed with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150615005826/en/
Source: Heron Therapeutics, Inc.
Investor Relations Contact:
Heron Therapeutics, Inc.
Sr. Manager, Investor Relations
Heron Therapeutics, Inc.
Vice President, Finance and Chief Financial Officer